HK Stock Market Move | PEGBIO CO-B(02565) increased by more than 5%. The preliminary form of review for the adjustment of the national medical insurance directory after 26 years has passed for the Peptide injection solution.

PEGBIO CO-B(02565) rose more than 5%, as of the time of reporting, it rose by 4.13% to 5.55 Hong Kong dollars, with a turnover of 39.0216 million Hong Kong dollars. On the news front, recently, PEGBIO CO-B announced that its core product, Vistafin peptide injection (trade name: Piedacon), has been included in the list of drugs for adjustment through preliminary review in the "2026 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue and Commercial Insurance Innovative Drug Catalogue" published by the National Medical Security Administration. It is listed as item 242 in the "Catalogue of Western Medicines and Chinese Patent Medicines- Basic Catalogue", categorized as a western medicine, meeting the criteria for "outside the catalogue condition 1", and marked as an exclusive variety. The Board of Directors believes that the inclusion of Vistafin peptide injection in the preliminary review of the 2026 National Medical Insurance Catalogue adjustment marks a key milestone in the post-market access process for this product after its listing. If the product is successfully included in the National Medical Insurance Catalogue, it is expected to significantly improve its accessibility, affordability for patients, and clinical coverage, further unlocking its commercial potential in the treatment of type 2 diabetes, and positively impacting the group's revenue growth, cash flow improvement, and revaluation of the core product value.